Figure legends
Figure 1: Biologic outcomes for Omalizumab and Mepolizumab at the end-of-trial. ACQ6: Asthma Control Questionnaire 6. AHE: acute healthcare encounters, which include Emergency department/ hospital admissions. OCS: oral corticosteroids. mg: milligrams. FEV1: forced expiratory volume in one second. AQLQ: Asthma Quality of Life Questionnaire. HADS: Hospital anxiety and depression scale.
Figure 2: Alternative assessments of biologic outcomes. Figure 2a: Side-by-side comparisons of different measures of biologic response. Figure 2b: Mepolizumab focused measures of biologic response. Numbers represent patient counts. ACQ: Asthma Control Questionnaire 6. AHE: acute healthcare encounters, which include Emergency department/ hospital admissions. OCS: Response with regard to exacerbations (incidence of exacerbations needing an acute OCS course or an increase in maintenance OCS dose). AQLQ: Asthma Quality of Life Questionnaire. MDT: multi-disciplinary team decision. Response for ACQ and AQLQ was defined as a reduction greater than the minimally important difference of ≥0.5. AHE response was defined as patients who had ≥1 AHE at baseline but now currently have no AHE. OCS response is defined as a reduction of maintenance OCS dose or exacerbations by ≥50%. MDT response is defined earlier in the methods. The blue outlier in figure 2a and 2b is a patient who reduced his maintenance OCS from 10-7mg and had no exacerbations nor AHE in the trial period (from a baseline of 0), and thereby had a positive trial.